Beth Hecht - 30 Jan 2026 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Chief Legal Officer and Corporate Secretary
Signature
/s/ Beth Hecht
Issuer symbol
XERS
Transactions as of
30 Jan 2026
Net transactions value
-$1,372,072
Form type
4
Filing time
02 Feb 2026, 18:11:11 UTC
Previous filing
05 Jan 2026
Next filing
04 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Hecht Beth Chief Legal Officer and Corporate Secretary C/O XERIS BIOPHARMA HOLDINGS, INC., 1375 WEST FULTON STREET, SUITE 1300, CHICAGO /s/ Beth Hecht 02 Feb 2026 0001652410

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Award $0 +121,293 +9.3% $0.000000 1,429,396 30 Jan 2026 Direct F1
transaction XERS Common Stock Tax liability $724,040 -98,375 -6.9% $7.36 1,331,021 31 Jan 2026 Direct F2
transaction XERS Common Stock Tax liability $345,287 -46,914 -3.5% $7.36 1,284,107 31 Jan 2026 Direct F2
transaction XERS Common Stock Tax liability $178,598 -24,266 -1.9% $7.36 1,259,841 31 Jan 2026 Direct F2
transaction XERS Common Stock Sale $124,147 -16,667 -1.3% $7.45 1,243,174 02 Feb 2026 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XERS Stock Option (Right to Buy) Award $0 +162,162 $0.000000 162,162 30 Jan 2026 Common Stock 162,162 $7.36 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued employment through such vesting date.
F2 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of January 31, 2026.
F3 The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.250 to $7.590, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service through such vesting date.

Remarks:

Chief Legal Officer and Corporate Secretary